🇺🇸 FDA
Patent

US 12077515

Selective histone deacetylase inhibitors for the treatment of human disease

granted A61KA61K31/165A61K31/433

Quick answer

US patent 12077515 (Selective histone deacetylase inhibitors for the treatment of human disease) held by Shuttle Pharmaceuticals, Inc. expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Shuttle Pharmaceuticals, Inc.
Grant date
Tue Sep 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/165, A61K31/433, A61K45/06, A61P